Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood

Patrick J Hanley¹, Catherine M Bollard², Claudio G Brunstein³

Affiliations

¹ Program for Cell Enhancement and Technologies for Immunotherapy, Children's National Medical Center and The George Washington University, Washington, DC, USA; Center for Cancer and Immunology Research, Children's National Medical Center and The George Washington University, Washington, DC, USA; Division of Blood and Marrow Transplantation, Children's National Medical Center and The George Washington University, Washington, DC, USA; Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Medical Center and The George Washington University, Washington, DC, USA. Electronic address: PHanley@childrensnational.org.
² Program for Cell Enhancement and Technologies for Immunotherapy, Children's National Medical Center and The George Washington University, Washington, DC, USA; Center for Cancer and Immunology Research, Children's National Medical Center and The George Washington University, Washington, DC, USA; Division of Blood and Marrow Transplantation, Children's National Medical Center and The George Washington University, Washington, DC, USA; Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Medical Center and The George Washington University, Washington, DC, USA.
³ Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA. Electronic address: Bruns072@umn.edu.

PMID: 25632003
PMCID: PMC4424101
DOI: 10.1016/j.jcyt.2014.12.007

Review

Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood

Patrick J Hanley et al. Cytotherapy. 2015 Jun.

. 2015 Jun;17(6):749-755.

doi: 10.1016/j.jcyt.2014.12.007. Epub 2015 Jan 24.

Authors

Patrick J Hanley¹, Catherine M Bollard², Claudio G Brunstein³

Affiliations

¹ Program for Cell Enhancement and Technologies for Immunotherapy, Children's National Medical Center and The George Washington University, Washington, DC, USA; Center for Cancer and Immunology Research, Children's National Medical Center and The George Washington University, Washington, DC, USA; Division of Blood and Marrow Transplantation, Children's National Medical Center and The George Washington University, Washington, DC, USA; Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Medical Center and The George Washington University, Washington, DC, USA. Electronic address: PHanley@childrensnational.org.
² Program for Cell Enhancement and Technologies for Immunotherapy, Children's National Medical Center and The George Washington University, Washington, DC, USA; Center for Cancer and Immunology Research, Children's National Medical Center and The George Washington University, Washington, DC, USA; Division of Blood and Marrow Transplantation, Children's National Medical Center and The George Washington University, Washington, DC, USA; Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Medical Center and The George Washington University, Washington, DC, USA.
³ Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA. Electronic address: Bruns072@umn.edu.

PMID: 25632003
PMCID: PMC4424101
DOI: 10.1016/j.jcyt.2014.12.007

Abstract

Cord blood transplantation, an alternative to traditional stem cell transplants (bone marrow or peripheral blood stem cell transplantation), is an attractive option for patients lacking suitable stem cell transplant donors. Cord blood units have also proven to be a valuable donor source for the development of cellular therapeutics. Virus-specific T cells and regulatory T cells are two cord blood-derived products that have shown promise in early-phase clinical trials to prevent and/or treat viral infections and graft-versus-host disease, respectively. We describe how current strategies that use cord blood-derived regulatory T cells and virus-specific T cells have been developed to improve outcomes for cord blood transplant recipients.

Keywords: antiviral; cell therapy; cord blood; graft-versus-host disease; immunotherapy; regulatory T cells (Treg); transplant.

PubMed Disclaimer

Figures

**Figure 1**
the cumulative incidence of garde II-IV acute GVHD by 100 for patients who received ex vivo expanded Tregs (**---**)and historical controls (⚊). (Adapted from Brunstein et al, 2011;117(3):1061–70).

See this image and copyright information in PMC

Cited by

Umbilical cord blood donation: public or private?
Ballen KK, Verter F, Kurtzberg J. Ballen KK, et al. Bone Marrow Transplant. 2015 Oct;50(10):1271-8. doi: 10.1038/bmt.2015.124. Epub 2015 Jun 1. Bone Marrow Transplant. 2015. PMID: 26030051 Review.
Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials.
McKenna DH Jr, Sumstad D, Kadidlo DM, Batdorf B, Lord CJ, Merkel SC, Koellner CM, Curtsinger JM, June CH, Riley JL, Levine BL, Miller JS, Brunstein CG, Wagner JE, Blazar BR, Hippen KL. McKenna DH Jr, et al. Cytotherapy. 2017 Feb;19(2):250-262. doi: 10.1016/j.jcyt.2016.10.011. Epub 2016 Nov 22. Cytotherapy. 2017. PMID: 27887864 Free PMC article.
Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy.
Fesnak AD, Hanley PJ, Levine BL. Fesnak AD, et al. Curr Hematol Malig Rep. 2017 Aug;12(4):335-343. doi: 10.1007/s11899-017-0395-9. Curr Hematol Malig Rep. 2017. PMID: 28762038 Free PMC article. Review.
Progress in Treatment of Viral Infections in Children with Acute Lymphoblastic Leukemia.
Moschovi M, Adamaki M, Vlahopoulos SA. Moschovi M, et al. Oncol Rev. 2016 Jun 30;10(1):300. doi: 10.4081/oncol.2016.300. eCollection 2016 Apr 15. Oncol Rev. 2016. PMID: 27471584 Free PMC article. Review.
Virus-Specific T Cells for the Immunocompromised Patient.
Houghtelin A, Bollard CM. Houghtelin A, et al. Front Immunol. 2017 Oct 11;8:1272. doi: 10.3389/fimmu.2017.01272. eCollection 2017. Front Immunol. 2017. PMID: 29075259 Free PMC article. Review.

See all "Cited by" articles

References

1. Sanchez-Fueyo A, Domenig CM, Mariat C, Alexopoulos S, Zheng XX, Strom TB. Influence of direct and indirect allorecognition pathways on CD4+CD25+ regulatory T-cell function in transplantation. Transpl Int. 2007;20(6):534–41. Epub 2007/03/17. - PMC - PubMed
1. Sakaguchi S. Regulatory T cells: history and perspective. Methods Mol Biol. 2011;707:3–17. Epub 2011/02/03. - PubMed
1. Barzaghi F, Passerini L, Bacchetta R. Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity. Frontiers in immunology. 2012;3:211. Epub 2012/10/13. - PMC - PubMed
1. Shen LS, Wang J, Shen DF, Yuan XL, Dong P, Li MX, et al. CD4(+)CD25(+)CD127(low/−) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol. 2009;131(1):109–18. Epub 2009/01/21. - PubMed
1. Yu N, Li X, Song W, Li D, Yu D, Zeng X, et al. CD4(+)CD25 (+)CD127 (low/−) T cells: a more specific Treg population in human peripheral blood. Inflammation. 2012;35(6):1773–80. Epub 2012/07/04. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood

Affiliations

Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood

Authors

Affiliations

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources